After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned Total of 600

Charles E. Edmiston , Ph.D., Emeritus Professor of Surgery, Medical College of Wisconsin , to discuss the significant unmet medical need in surgical site infections prevention Company to Provide an Update on SHIELD II Phase 3 Study Enrollment During Event PETACH TIKVA, Israel , June 10, 2024 (GLOBE

More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections Approximately 50 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients   Complete Their 30-Day Follow-up;

PETACH TIKVA, Israel , May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New

Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Second Half of 2024 PETACH TIKVA, Israel , April 30, 2024 (GLOBE NEWSWIRE) -- PolyPid

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26 th Annual Global

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients   Complete Their 30-Day Follow-up; Top-line Results Expected in Second

Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients   Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Recent Successful $16 Million Financing Extends Company’s Cash Runway Through Late Q3 2024 and

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational